Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation

A. Lauro, A. Dazzi, G. Ercolani, C. Zanfi, L. Golfieri, A. Amaduzzi, A. Cucchetti, G. La Barba, G. L. Grazi, A. D'Errico, M. Vivarelli, M. Cescon, G. Varotti, M. Del Gaudio, M. Ravaioli, M. Di Simone, S. Faenza, L. Pironi, A. D. Pinna

Research output: Contribution to journalArticle

Abstract

Purpose: Mammalian target of rapamycin (mTOR) inhibitors have been recently introduced in clinical practice after intestinal transplantation. We focused on Sirolimus (Rapamycin) to examine effects on rejection and graft survival following intestinal transplantation. Patients and methods: Twenty isolated intestinal recipients and 5 multivisceral patients (2 with liver) in our series were divided into 3 groups: patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who continued therapy longer than 3 months (n = 11); patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who received therapy less than 3 months because of side effects (n = 4); and a control group, who never received rapamycin (n = 10). Results: During prolonged treatment combined with Tacrolimus (Prograf), both Sirolimus groups showed a decreased number of acute cellular rejections (P <.01). Cumulative 3-year graft and patient survival rates were 81% in the Sirolimus greater than 3 months group, 100% in the Sirolimus less than 3 months group, and 80% and 90% in the control group, respectively (P = .63 and P = .62). Conclusion: In our experience, the use of mTOR-inhibitors in combination with calcineurin-inhibitors seemed to be more effective than monotherapy to reduce the number of rejections. Side effects can limit its use as maintenance therapy.

Original languageEnglish
Pages (from-to)1629-1631
Number of pages3
JournalTransplantation Proceedings
Volume39
Issue number5
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Tacrolimus
Graft Survival
Sirolimus
Transplantation
Therapeutics
Biopsy
Control Groups
Survival Rate
Liver

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation. / Lauro, A.; Dazzi, A.; Ercolani, G.; Zanfi, C.; Golfieri, L.; Amaduzzi, A.; Cucchetti, A.; La Barba, G.; Grazi, G. L.; D'Errico, A.; Vivarelli, M.; Cescon, M.; Varotti, G.; Del Gaudio, M.; Ravaioli, M.; Di Simone, M.; Faenza, S.; Pironi, L.; Pinna, A. D.

In: Transplantation Proceedings, Vol. 39, No. 5, 06.2007, p. 1629-1631.

Research output: Contribution to journalArticle

Lauro, A, Dazzi, A, Ercolani, G, Zanfi, C, Golfieri, L, Amaduzzi, A, Cucchetti, A, La Barba, G, Grazi, GL, D'Errico, A, Vivarelli, M, Cescon, M, Varotti, G, Del Gaudio, M, Ravaioli, M, Di Simone, M, Faenza, S, Pironi, L & Pinna, AD 2007, 'Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation', Transplantation Proceedings, vol. 39, no. 5, pp. 1629-1631. https://doi.org/10.1016/j.transproceed.2007.02.067
Lauro, A. ; Dazzi, A. ; Ercolani, G. ; Zanfi, C. ; Golfieri, L. ; Amaduzzi, A. ; Cucchetti, A. ; La Barba, G. ; Grazi, G. L. ; D'Errico, A. ; Vivarelli, M. ; Cescon, M. ; Varotti, G. ; Del Gaudio, M. ; Ravaioli, M. ; Di Simone, M. ; Faenza, S. ; Pironi, L. ; Pinna, A. D. / Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation. In: Transplantation Proceedings. 2007 ; Vol. 39, No. 5. pp. 1629-1631.
@article{5adb6977069b447a8df0716132ccc7be,
title = "Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation",
abstract = "Purpose: Mammalian target of rapamycin (mTOR) inhibitors have been recently introduced in clinical practice after intestinal transplantation. We focused on Sirolimus (Rapamycin) to examine effects on rejection and graft survival following intestinal transplantation. Patients and methods: Twenty isolated intestinal recipients and 5 multivisceral patients (2 with liver) in our series were divided into 3 groups: patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who continued therapy longer than 3 months (n = 11); patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who received therapy less than 3 months because of side effects (n = 4); and a control group, who never received rapamycin (n = 10). Results: During prolonged treatment combined with Tacrolimus (Prograf), both Sirolimus groups showed a decreased number of acute cellular rejections (P <.01). Cumulative 3-year graft and patient survival rates were 81{\%} in the Sirolimus greater than 3 months group, 100{\%} in the Sirolimus less than 3 months group, and 80{\%} and 90{\%} in the control group, respectively (P = .63 and P = .62). Conclusion: In our experience, the use of mTOR-inhibitors in combination with calcineurin-inhibitors seemed to be more effective than monotherapy to reduce the number of rejections. Side effects can limit its use as maintenance therapy.",
author = "A. Lauro and A. Dazzi and G. Ercolani and C. Zanfi and L. Golfieri and A. Amaduzzi and A. Cucchetti and {La Barba}, G. and Grazi, {G. L.} and A. D'Errico and M. Vivarelli and M. Cescon and G. Varotti and {Del Gaudio}, M. and M. Ravaioli and {Di Simone}, M. and S. Faenza and L. Pironi and Pinna, {A. D.}",
year = "2007",
month = "6",
doi = "10.1016/j.transproceed.2007.02.067",
language = "English",
volume = "39",
pages = "1629--1631",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation

AU - Lauro, A.

AU - Dazzi, A.

AU - Ercolani, G.

AU - Zanfi, C.

AU - Golfieri, L.

AU - Amaduzzi, A.

AU - Cucchetti, A.

AU - La Barba, G.

AU - Grazi, G. L.

AU - D'Errico, A.

AU - Vivarelli, M.

AU - Cescon, M.

AU - Varotti, G.

AU - Del Gaudio, M.

AU - Ravaioli, M.

AU - Di Simone, M.

AU - Faenza, S.

AU - Pironi, L.

AU - Pinna, A. D.

PY - 2007/6

Y1 - 2007/6

N2 - Purpose: Mammalian target of rapamycin (mTOR) inhibitors have been recently introduced in clinical practice after intestinal transplantation. We focused on Sirolimus (Rapamycin) to examine effects on rejection and graft survival following intestinal transplantation. Patients and methods: Twenty isolated intestinal recipients and 5 multivisceral patients (2 with liver) in our series were divided into 3 groups: patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who continued therapy longer than 3 months (n = 11); patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who received therapy less than 3 months because of side effects (n = 4); and a control group, who never received rapamycin (n = 10). Results: During prolonged treatment combined with Tacrolimus (Prograf), both Sirolimus groups showed a decreased number of acute cellular rejections (P <.01). Cumulative 3-year graft and patient survival rates were 81% in the Sirolimus greater than 3 months group, 100% in the Sirolimus less than 3 months group, and 80% and 90% in the control group, respectively (P = .63 and P = .62). Conclusion: In our experience, the use of mTOR-inhibitors in combination with calcineurin-inhibitors seemed to be more effective than monotherapy to reduce the number of rejections. Side effects can limit its use as maintenance therapy.

AB - Purpose: Mammalian target of rapamycin (mTOR) inhibitors have been recently introduced in clinical practice after intestinal transplantation. We focused on Sirolimus (Rapamycin) to examine effects on rejection and graft survival following intestinal transplantation. Patients and methods: Twenty isolated intestinal recipients and 5 multivisceral patients (2 with liver) in our series were divided into 3 groups: patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who continued therapy longer than 3 months (n = 11); patients started on Sirolimus (because of nephrotoxicity or biopsy-proven rejection), who received therapy less than 3 months because of side effects (n = 4); and a control group, who never received rapamycin (n = 10). Results: During prolonged treatment combined with Tacrolimus (Prograf), both Sirolimus groups showed a decreased number of acute cellular rejections (P <.01). Cumulative 3-year graft and patient survival rates were 81% in the Sirolimus greater than 3 months group, 100% in the Sirolimus less than 3 months group, and 80% and 90% in the control group, respectively (P = .63 and P = .62). Conclusion: In our experience, the use of mTOR-inhibitors in combination with calcineurin-inhibitors seemed to be more effective than monotherapy to reduce the number of rejections. Side effects can limit its use as maintenance therapy.

UR - http://www.scopus.com/inward/record.url?scp=34250173389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250173389&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2007.02.067

DO - 10.1016/j.transproceed.2007.02.067

M3 - Article

C2 - 17580204

AN - SCOPUS:34250173389

VL - 39

SP - 1629

EP - 1631

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -